TrialThe Lancet. Haematology2025

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.

Modupe Idowu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.